## DT15 Rec'd PCT/PTO 28 FEB 2005

PCT/EP2003/009437

## WO 2004/020665

- 1 -

SEQUENCE LISTING <110> Evotec NeuroSciences GmbH <120> Diagnostic and therapeutic use of FOAP-13 polynucleotides and polypeptides for neurodegenerative diseases <130> 031985wo ME/BM <140> <141> <150> 02019281.1 <151> 2002-08-28 <160> 18 <170> PatentIn Ver. 2.1 <210> 1 <211> 390 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: cDNA fragment of the foap-13 gene <400> 1 tggttcctgg ctctccctca agagtgcagc cttggctaga gaactcacag ctctgggaaa 60 aagaggagca gacagggttc cctgggccca gtctcagecc agccactgat gctggatgac 120 cttggcctga ccctggtctg gtctcagaat cacttttccc atctgtaaaa ttgagatgaa 180 ttttggtgtt gaaagttctt cctggagcag atgtcctaga aggttttagg aatagtgaca 240 gagtcaggcc accccaaggg ccatgggagc cagctgacct gcttgaccga aggatttctg 300 acagactatc tttggggatg ttttcaagaa gggatataag ttatttactt tgggcattta 360 aaagaaaatt tctctcggga ataattttat <210> 2 <211> 491 <212> PRT <213> Homo sapiens <400> 2 Met Ala Gly Gln Gly Leu Pro Leu His Val Ala Thr Leu Leu Thr Gly Leu Leu Glu Cys Leu Gly Phe Ala Gly Val Leu Phe Gly Trp Pro Ser Leu Val Phe Val Phe Lys Asn Glu Asp Tyr Phe Lys Asp Leu Cys Gly Pro Asp Ala Gly Pro Ile Gly Asn Ala Thr Gly Gln Ala Asp Cys Lys Ala Gln Asp Glu Arg Phe Ser Leu Ile Phe Thr Leu Gly Ser Phe Met 65

Asn Asn Phe Met Thr Phe Pro Thr Gly Tyr Ile Phe Asp Arg Phe Lys

90

Thr	Thr	Val	Ala 100	Arg	Leu	Ile	Ala	Ile 105		Phe	Tyr	Thr	Thr		Thr
Leu	Ile	Ile 115	Ala	Phe	Thr	Ser	Ala 120		Ser	Ala	Val	Leu 125		Phe	Leu
Ala	Met 130	Pro	Met	Leu	Thr	Ile 135		Gly	Ile	Leu	Phe 140		Ile	Thr	Asn
Leu 145	Gln	Ile	Gly	Asn ·	Leu 150	Phe	Gly	Gln	His	Arg 155		Thr	Ile	Ile	Thr 160
Leu	Tyr	Asn	Gly	Ala 165	Phe	Asp	Ser	Ser	Ser 170		Val	Phe	Leu	Ile 175	
Lys	Leu	Leu	Tyr 180	Glu	Lys	Gly	Ile	Ser 185	Leu	Arg	Ala	Ser	Phe 190	Ile	Phe
Ile	Ser	Val 195	Cys	Ser	Thr	Trp	His 200	Val	Ala	Arg	Thr	Phe 205		Leu	Met
Pro	Arg 210	Gly	His	Ile	Pro	Tyr 215	Pro	Leu	Pro	Pro	Asn 220	Tyr	Ser	Tyr	Gly
Leu 225	Cys	Pro	Gly	Asn	Gly 230	Thr	Thr	Lys	Glu	Glu 235	Lys	Glu	Thr	Ala	Glu 240
His	Gl'n	Asn	Arg	Glu 245	Leu	Gln	Ser	Lys	Glu 250	Phe	Leu	Ser	Ala	Lys 255	Glu
Glu	Thr	Pro	Gly 260	Ala	Gly	Gln	Lys	Gln 265	Glu	Leu	Arg	Ser	Phe 270	Trp	Ser
Tyr	Ala	Phe 275	Ser	Arg	Arg	Phe	Ala 280	Trp	His	Leu	Val	Trp 285	Leu	Ser	Val
Ile	Gln 290	Leu	Trp	His	Tyr	Leu 295	Phe	Ile	Gly	Thr	Leu 300	Asn	Ser	Leu	Leu
Thr 305	Asn	Met	Ala	Gly	Gly 310	Asp	Met	Ala	Arg	Val 315	Ser	Thr	Tyr	Thr	Asn 320
Ala	Phe	Ala	Phe	Thr 325	Gln	Phe	Gly	Val	Leu 330	Cys	Ala	Pro	Trp	Asn 335	Gly
Leu	Leu	Met	Asp 340	Arg	Leu	Lys	Gln	Lys 345	Tyr	Gln	Lys	Glu	Ala 350	Arg	Lys
Thr	Gly	Ser 355	Ser	Thr	Leu	Ala	Val 360	Ala	Leu	Cys	Ser	Thr 365	Val	Pro	Ser
Leu	Ala 370	Leu	Thr	Ser	Leu	Leu 375	Cys	Leu	Gly	Phe	Ala 380	Leu	Cys	Ala	Ser
Val 385	Pro	Ile	Leu	Pro	Leu 390	Gln	Туг	Leu	Thr	Phe 395	Ile	Leu	Gln	Val	Ile 400
Ser	Arg	Ser	Phe	Leu 405	Tyr	Gly	Ser	Asn	Ala 410	Ala	Phe	Leu	Thr	Leu 415	Ala
Phe	Pro	Ser	Glu	His	Phe	Gly	Lys	Leu	Phe	Gly	Leu	Val	Met	Ala	Leu

WO 2004/020665 PCT/EP2003/009437

- 3 -

420 425 430

Ser Ala Val Val Ser Leu Leu Gln Phe Pro Ile Phe Thr Leu Ile Lys 435 440 445

Gly Ser Leu Gln Asn Asp Pro Phe Tyr Val Asn Val Met Phe Met Leu 450 455 460

Ala Ile Leu Leu Thr Phe Phe His Pro Phe Leu Val Tyr Arg Glu Cys 465 470 475 480

Arg Thr Trp Lys Glu Ser Pro Ser Ala Ile Ala 485 490

<210> 3

<211> 2630

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: cDNA of the
human foap-13 gene

<400> 3

cggacgcgtg ggcggacgcg tgggcggacg cgtgggctct gggagtgtga aactgggaga 60 gacggttaag ctggggacgg tattcagaat tcgagcgcag gagctccgct tctccacctg 120 ctcccgggga gctattggga tccagagaat cacccgctga tggtttttcc ccaggcctga 180 aacaaccaga gagctacggg aaaggaaggg cttggcttgc cagaggaatt ttccaagtgc 240 tcaaacgcca ggcttacggc gcctgtgatc cgtccaggag gacaaagtgg gatttgaaga 300 tecaetecae ttetgeteat ggegggeeag ggeetgeece tgcaegtgge caeaetgetg 360 actgggctgc tggaatgcct gggctttgct ggcgtcctct ttggctggcc ttcactagtg 420 tttgtcttca agaatgaaga ttactttaag gatctgtgtg gaccagatgc tgggccgatt 480 ggcaatgcca cagggcaggc tgactgcaaa gcccaggatg agaggttctc actcatcttc 540 accetggggt cetteatgaa caactteatg acatteecea etggetaeat etttgaeegg 600 ttcaagacca ccgtggcacg cctcatagcc atatttttct acaccaccgc cacactcatc 660 atageettea cetetgeagg eteageegtg etgetettee tggeeatgee aatgeteace 720 attgggggaa tectgtttet cateaceaec etgeagattg ggaacetatt tggccaacac 780 cgttcgacca tcatcactct gtacaatgga gcatttgact cttcctcggc agtcttcctt 840 attattaage ttetttatga aaaaggeate ageeteaggg ceteetteat etteatetet 900 gtotgcagta cotggcatgt agcacgcact ttcctcctga tgccccgggg gcacatccca 960 tacccactge ecceeaacta cagetatgge etgtgeeetg ggaatggeac cacaaaggaa 1020 gagaaggaaa cagctgagca tgaaaacagg gagctacagt caaaggagtt cctttcagcg 1080 aaggaagaga ccccaggggc agggcagaag caggaactcc gctccttctg gagctacgct 1140 ttctctcggc gctttgcctg gcacctggtg tggctgtctg tgatacagtt gtggcactac 1200 ctetteattg geacteteaa eteettgetg accaacatgg ceggtgggga catggcaega 1260 gtcagcacct acacaaatgc ctttgccttc actcagttcg gagtgctgtg tgccccctgg 1320 aatggcctgc tcatggaccg gcttaaacag aagtaccaga aggaagcaag aaagacaggt 1380 tectecactt tggcggtggc cetetgeteg acggtgeett egetggeeet gacatecetg 1440 ctgtgcctgg gcttcgccct ctgtgcctca gtccccatcc tecctctcca gtacctcacc 1500 ttcatcctgc aagtgatcag ccgctccttc ctctatggga gcaacgcggc cttcctcacc 1560 cttgctttcc cttcagagca ctttggcaag ctctttgggc tggtgatggc cttgtcggct 1620 gtggtgtctc tgctccagtt ccccatcttc accctcatca aaggctccct tcagaatgac 1680 ccattitacg tgaatgtgat gttcatgctt gccattcttc tgacattctt ccaccccttt 1740 ctggtatatc gggaatgccg tacttggaaa gaaagtccct ctgcaattgc atagttcaga 1800 agcoctcact tttcagcccc gaggatggtt ttgttcatct tccaccacct ttgaggacct 1860 cgtgtcccaa aagactttgc ctatcccagc aaaacacaca cacacacaca cacacaca 1920 aaataaagac acacaaggac gtctgcgcag caagaaaaga atctcagttg ccaagcagat 1980 tgatatcaca cagactcaaa gcaaaggcat gtggaacttc tttatttcaa aacagaagtg 2040 teteettgea ettageettg geagaceett gaeteeaggg gagatgaeet gggggaggaa 2100 gtgtgtcaac tatttcttta ggcctgtttg gctccgaagc ctatatgtgc ctggatcctc 2160 tgccacgggt taaattttca ggtgaagagt gaggttgtca tggcctcagc tatgcttcct 2220

WO 2004/020665 PCT/EP2003/009437

- 4 -

```
ggctctccct caagagtgca gccttggcta gagaactcac agctctggga aaaagaggag 2280
cagacagggt tecetgggcc cagteteage ceagecactg atgetggatg acettggect 2340
gaccctggtc tggtctcaga atcacttttc ccatctgtaa aattgagatg aattttggtg 2400
ttgaaagttc ttcctggagc agatgtccta gaaggtttta ggaatagtga cagagtcagg 2460
ccacccaag ggccatggga gccagctgac ctgcttgacc gaaggatttc tgacagacta 2520 tctttgggga tgttttcaag aagggatata agttatttac tttgggcatt taaaagaaaa 2580
tttctctcgg gaataatttt atagaaaaat aaagcttctg tgtctaaggc
                                                                        2630
<210> 4
<211> 13
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: one-base
      anchor oligonucleotide
<400> 4
htttttttt tta
                                                                        13
<210> 5
<211> 13
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: one-base
      anchor oligonucleotide
<400> 5
htttttttt ttg
                                                                        13
<210> 6
<211> 13
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: one-base
                                                                                        )
      anchor oligonucleotide
<400> 6
htttttttt ttc
                                                                       13
<210> 7
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for the
      foap-13 gene
<400> 7
tcaggtgaag agtgaggttg tca
                                                                       23
```

<210> 8

- 5 -

<211> <212> <213>		
<220> <223>	Description of Artificial Sequence: primer for the foap-13 gene	
<400> ggctg	8 cactc ttgagggaga	20
<210> <211> <212> <213>	20	
<220> <223>	Description of Artificial Sequence: primer for the cyclophilin B gene	
<400> actgaa	9 agcac tacgggcctg	20
<210> <211> <212> <213>	19	
<220> <223>	Description of Artificial Sequence: primer for the cyclophilin B gene	
<400> agccgt	10 tggt gtctttgcc	19
<210> <211> <212> <213>	20	
	Description of Artificial Sequence: primer for the ribosomal protein S9	
(400> ggtcaa	11 ' lattt accctggcca	20
(210> (211> (212> (213>	22	
	Description of Artificial Sequence: primer for the ribosomal protein S9	
400> ctcat	12 caag cgtcagcagt tc	22

i

}

<210> <211> <212> <213>	19	
<220> <223>	Description of Artificial Sequence: primer for the beta-actin gene	
<400> tggaad	13 eggtg aaggtgaca	19
<210> <211> <212> <213>	19	
<220> <223>	Description of Artificial Sequence: primer for the beta-actin gene	
<400> ggcaaq	14 gggac ttcctgtaa	19
<210> <211> <212> <213>	20	
<220> <223>	Description of Artificial Sequence: primer for the GAPDH gene	
<400> cgtcat	15 gggt gtgaaccatg	20
<210> <211> <212> <213>	21	
<220> <223>	Description of Artificial Sequence: primer for the GAPDH gene	
<400> gctaag	16 cagt tggtggtgca g	21
<210> <211> <212> <213>	21	
<220> <223>	Description of Artificial Sequence: primer for the transferrin receptor (TRR)	

WO 2004/020665 PCT/EP2003/009437

- 7 -

<400> 17 gtcgctggtc agttcgtgat t	21
<210> 18 <211> 23 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer for the transferrin receptor (TRR)	
<400> 18 agcagttggc tgttgtacct ctc	23